Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach

[1]  J. Nielsen,et al.  Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning , 2021, iScience.

[2]  Y. Seong,et al.  Anaplastic lymphoma kinase inhibitor NVP‑TAE684 suppresses the proliferation of human pancreatic adenocarcinoma cells. , 2021, Oncology reports.

[3]  Tetsutaro Hayashi,et al.  BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma , 2021, Oncology.

[4]  J. de Magalhães,et al.  Ageing transcriptome meta-analysis reveals similarities and differences between key mammalian tissues , 2021, Aging.

[5]  S. Orsulic,et al.  Identification of Infertility-Associated Topologically Important Genes Using Weighted Co-expression Network Analysis , 2021, Frontiers in Genetics.

[6]  Yahui Wang,et al.  Identification of Core Genes Involved in the Metastasis of Clear Cell Renal Cell Carcinoma , 2020, Cancer management and research.

[7]  Yaohang Li,et al.  Computational drug repositioning based on multi-similarities bilinear matrix factorization , 2020, Briefings Bioinform..

[8]  M. Rausch,et al.  Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance , 2020, Cancers.

[9]  S. Hancock,et al.  NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  Gesine Reinert,et al.  COGENT: evaluating the consistency of gene co-expression networks , 2020, bioRxiv.

[11]  Mathias Uhlen,et al.  Current Status of COVID-19 Therapies and Drug Repositioning Applications , 2020, iScience.

[12]  Yaohang Li,et al.  Biomedical data and computational models for drug repositioning: a comprehensive review , 2020, Briefings Bioinform..

[13]  Vasileios Stathias,et al.  LINCS Data Portal 2.0: next generation access point for perturbation-response signatures , 2019, Nucleic Acids Res..

[14]  Ping Xuan,et al.  Drug repositioning through integration of prior knowledge and projections of drugs and diseases , 2019, Bioinform..

[15]  Jens Nielsen,et al.  Systems biology based drug repositioning for development of cancer therapy. , 2019, Seminars in cancer biology.

[16]  T. Sakaguchi,et al.  Potential tumor‑suppressive role of microRNA‑99a‑3p in sunitinib‑resistant renal cell carcinoma cells through the regulation of RRM2. , 2019, International journal of oncology.

[17]  H. Kume,et al.  Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers , 2019, bioRxiv.

[18]  Wang Tianyu,et al.  Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma. , 2019, Biochemical and biophysical research communications.

[19]  Jens Nielsen,et al.  Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes , 2018, Proceedings of the National Academy of Sciences.

[20]  J. Nielsen,et al.  Systems biology in hepatology: approaches and applications , 2018, Nature Reviews Gastroenterology & Hepatology.

[21]  H. Guchelaar,et al.  Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression , 2018, Scientific Reports.

[22]  A. Difeo,et al.  Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment , 2017, Oncogene.

[23]  C. Lindskog,et al.  A pathology atlas of the human cancer transcriptome , 2017, Science.

[24]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[25]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[26]  Charles Swanton,et al.  Renal cell carcinoma , 2017, Nature Reviews Disease Primers.

[27]  I. Kovalszky,et al.  Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. , 2016, American journal of cancer research.

[28]  Stephen R. Piccolo,et al.  A cloud-based workflow to quantify transcript-expression levels in public cancer compendia , 2016, Scientific Reports.

[29]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[30]  Y. Li,et al.  NVP‐TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P‐glycoprotein (PGP1) function , 2016, British journal of pharmacology.

[31]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[32]  J. Laubach,et al.  Panobinostat for the Treatment of Multiple Myeloma , 2015, Clinical Cancer Research.

[33]  Bong-Woo Kim,et al.  Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity , 2015, Journal of cancer prevention.

[34]  Natapol Pornputtapong,et al.  Human metabolic atlas: an online resource for human metabolism , 2015, Database J. Biol. Databases Curation.

[35]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[36]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[37]  A. Sato,et al.  Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells , 2014, BMC Urology.

[38]  Andrew L. Kung,et al.  Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer , 2014, Molecular Cancer Therapeutics.

[39]  G. Mocz,et al.  Withaferin A Inhibits STAT3 and Induces Tumor Cell Death in Neuroblastoma and Multiple Myeloma , 2014, Biochemistry insights.

[40]  H. Aburatani,et al.  Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.

[41]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[42]  J. Christensen,et al.  Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells , 2012, Oncogene.

[43]  Dong Eun Kim,et al.  Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. , 2012, Biochemical and biophysical research communications.

[44]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[45]  J. Hainsworth,et al.  A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma , 2011, Cancer investigation.

[46]  D. Carbone,et al.  Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[47]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[48]  E. Barillot,et al.  Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer , 2011, The EMBO journal.

[49]  Shivendra V. Singh,et al.  Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. , 2010, Carcinogenesis.

[50]  S. Vincent Rajkumar,et al.  TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells , 2010, American journal of hematology.

[51]  X. Hua,et al.  Regulation of Cyclin B2 Expression and Cell Cycle G2/M Transition by Menin* , 2010, The Journal of Biological Chemistry.

[52]  Gyan Bhanot,et al.  Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns , 2010 .

[53]  Gyan Bhanot,et al.  Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. , 2010, Genes & cancer.

[54]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[55]  Y. Yen,et al.  Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis , 2009, Molecular Cancer.

[56]  Sheng-Tang Wu,et al.  Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells , 2009, Clinical Cancer Research.

[57]  Jingtai Han.  Understanding biological functions through molecular networks , 2008, Cell Research.

[58]  D. Gilliland,et al.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.

[59]  T. Hunt,et al.  The Crystal Structure of Human Cyclin B , 2007, Cell cycle.

[60]  Peter G. Schultz,et al.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.

[61]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[62]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[63]  Matthieu Latapy,et al.  Computing Communities in Large Networks Using Random Walks , 2004, J. Graph Algorithms Appl..

[64]  H. Hammers,et al.  Withaferin A is a potent inhibitor of angiogenesis , 2004, Angiogenesis.

[65]  Lani F. Wu,et al.  Multidimensional Drug Profiling By Automated Microscopy , 2004, Science.

[66]  Joshua M. Stuart,et al.  A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules , 2003, Science.

[67]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[68]  David Beach,et al.  cdc2 protein kinase is complexed with both cyclin A and B: Evidence for proteolytic inactivation of MPF , 1989, Cell.

[69]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[70]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[71]  D. Gilliland,et al.  TG 101209 , a small molecule JAK 2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK 2 V 617 F and MPL W 515 L / K mutations , 2007 .

[72]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .

[73]  R. Goorha,et al.  The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is expressed in a cell cycle-dependent manner. , 1999, Genomics.